As of Friday close, Atara Biotherapeutics Inc.’s (NASDAQ:ATRA) stock was down -$0.07, moving down -2.27 percent to $3.02. The average number of shares traded per day over the past five days has been 2,090,680 shares. 2 times new highs have been achieved over the past 5 days, with a $0.19 gain in that time frame. In the last twenty days, the average volume was 1,286,765, while in the previous 50 days, it was 1,139,354.
Since last month, ATRA stock retreated -33.33%. Shares of the company fell to $2.66 on 03/10/23, the lowest level in the past month. A 52-week high of $10.01 was reached on 02/06/23 after having rallying from a 52-week low of $2.66. Since the beginning of this year, ATRA’s stock price has dropped by -7.93% or -$0.26, and marked a new high 14 times. However, the stock has declined by -69.83% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
ATRA stock investors should be aware that Atara Biotherapeutics Inc. (ATRA) stock had its last reported insider trading activity 16 days ago on Mar 02. Touchon Pascal, the President and CEO of the company, disposed of 15,679 shares for $3.63 on Mar 02. It resulted in a $56,868 divestment by the insider. Koppikar Utpal sold 6,871 shares at an average price of $3.63 on Mar 02. The insider now owns 181,978 shares following the transaction. On Mar 02, EVP, Head of R&D Dupont Jakob sold 5,074 shares at $3.63 apiece. The transaction was valued at $18,403.
Valuation Metrics
The stock’s beta is 1.02. Besides these, the trailing price-to-sales (P/S) ratio of 5.02, the price-to-book (PB) ratio of 2.46.
Financial Health
In the three months ended December 30, Atara Biotherapeutics Inc.’s quick ratio stood at 3.70, while its current ratio was 3.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.03, and the total debt-to-equity ratio was 0.03. Based on annual data, ATRA earned $344.09 million in gross profit and brought in $63.57 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -214.10%. Return on equity (ROE) for the past 12 months was -114.80%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ATRA’s revenue fell -20.4% to $51.58 million during the quarter, while net income inched up to $4.46 million. While analysts expected Atara Biotherapeutics Inc. to report -$0.51 quarterly earnings, the actual figure was -$0.72 per share, beating the consensus estimate by -41.20%. During the quarter, the company generated -$74.23 million in EBITDA. The liabilities of Atara Biotherapeutics Inc. were 249.78 million at the end of its most recent quarter ended December 30, and its total debt was $75.35 million. The value of shareholders’ equity is $95.93 million.
Technical Picture
This quick technical analysis looks at Atara Biotherapeutics Inc.’s (ATRA) price momentum. With a historical volatility rate of 81.06%, the RSI 9-day stood at 30.78% on 17 March.
With respect to its five-day moving average, the current Atara Biotherapeutics Inc. price is up by +6.71% percent or $0.19. At present, ATRA shares trade -30.41% below its 20-day simple moving average and -28.61% percent below its 100-day simple moving average. However, the stock is currently trading approximately -9.85% below its SMA50 and -41.92% below its SMA200.
Stochastic coefficient K was 26.11% and Stochastic coefficient D was 27.97%, while ATR was 0.27. Given the Stochastic reading of 23.30% for the 14-day period, the RSI (14) reading has been calculated as 33.89%. As of today, the MACD Oscillator reading stands at -0.05, while the 14-day reading stands at -0.26.
Analyst Ratings
Atara Biotherapeutics Inc. downgraded its rating on Atara Biotherapeutics Inc. (NASDAQ: ATRA) to a Sell in a note to investors on July 20, 2022. The analysts firm previously had a Neutral rating on the stock.Atara Biotherapeutics Inc. (ATRA) has been rated Overweight by analysts. According to 2 brokerage firms, ATRA is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Atara Biotherapeutics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $25.00, the current consensus forecast for the stock is $2.00 – $50.00. Based on these forecasts, analysts predict Atara Biotherapeutics Inc. (ATRA) will achieve an average price target of $20.43.